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Introduction
Peritoneal metastasis (PM) is a sinister denominator 
of various primary tumors, originating mainly from 
the gastrointestinal tract or ovaries. Patients with 
PM have a poor quality of life, short life expectancy 
and are troubled by deteriorating symptoms, such as 
abdominal pain, ascites and bowel obstruction.1–5 
The standard treatment is palliative systemic chem-
otherapy or best supportive care, apart from highly 
selected patients with limited PM from ovarian or 
colorectal cancer, who are eligible for cytoreductive 
surgery.6,7 Systemic chemotherapy has a docu-
mented effect in a broad range of primary malignan-
cies with disseminated disease (e.g. liver and lung 
metastases), but in contrast the evidence regarding 
patients with isolated PM is scarce and incomplete.5 
This may be due to the patients’ poor performance 
status and the fact that small-volume PM and ascites 
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Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a laparoscopy-
guided administration of aerosolized chemotherapy. PIPAC seems to improve objective tumor 
response, survival and quality of life in patients with peritoneal metastasis. We assessed 
feasibility and efficacy of PIPAC in patients with peritoneal metastasis (PM).
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for healthcare workers. The mean PRGS was reduced significantly and a reduction of the 
PRGS was seen in 67% of the patients. Conversion from positive to negative cytology was 
achieved in 23% of the patients. Quality of life was stabilized from baseline to day 60.
Conclusions: PIPAC is feasible and well tolerated, may stabilize the quality of life in patients 
with end-stage PM and may induce histological and cytological regression.
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are nonmeasurable lesions according to Response 
Evaluation Criteria In Solid Tumors (RECIST) cri-
teria,8 which impedes response evaluation.
As PM is confined to the abdominal cavity, intra-
peritoneal administration of chemotherapy seems 
obvious. Due to low penetration rates, catheter-
related complications and challenging treatment 
logistics,9–13 the results are still ambiguous. A 
novel intraperitoneal treatment approach has 
recently been introduced, where aerosolized 
chemotherapeutics are emitted within the perito-
neal cavity during a standard laparoscopy at a 
capnoperitoneum of 12 mmHg, the so-called 
‘pressurized intraperitoneal aerosol chemother-
apy’ (PIPAC).14–16 PIPAC is an experimental 
treatment strategy, and there are no randomized, 
controlled trials confirming the first preliminary 
data, and according to recent reviews, the onco-
logical efficacy must be upheld in prospective 
clinical trials.17,18 Still, administration of intra-
peritoneal chemotherapy by PIPAC seems well 
tolerated and able to induce histological regres-
sion, improve or stabilize quality of life and may 
even lead to prolonged survival.19–27 This is 
remarkable, as the dose of chemotherapy admin-
istered during PIPAC is substantially reduced, 
when comparing with the normal systemic dose, 
and the included patients are often heavily pre-
treated with platinum-based combination chemo-
therapy regimens. Still, the available studies are 
mostly preclinical or retrospective17 and con-
strained by lacking baseline histology, which 
obscures the influence of histological response to 
prior systemic chemotherapy.
Study rationale
PIPAC is a combined surgical and oncological 
palliative treatment modality in patients with iso-
lated PM from any origin. The main outcome of 
this prospective clinical study, is to document fea-
sibility of PIPAC. Second, we evaluate the PIPAC 
treatment by using strict predefined response 
evaluation criteria and report this new response 
evaluation strategy.
Materials and methods
Patients were included from March 2015 to 
October 2016 and the last PIPAC was completed 
in July 2017. Patients were eligible for data analy-
sis from the day of admission for the first PIPAC 
procedure. Inclusion criteria were patients with 
isolated PM who (1) progressed on standard 
palliative systemic chemotherapy, or (2) refused 
systemic chemotherapy, or (3) patients who, at 
the discretion of the medical oncologist, were inel-
igible for further systemic chemotherapy, due to 
treatment-related side effects (e.g. fatigue, neu-
ropathy, nausea). Patients with Eastern 
Cooperative Oncology Group (ECOG) perfor-
mance status >2, age ⩽ 18 years, bowel obstruc-
tion (total parenteral nutrition, nasogastric tube), 
history of platinum allergy, impaired liver, renal, 
heart (New York Heart Association class >2) or 
bone marrow function, and patients with extra-
peritoneal metastases on contrast-enhanced multi-
slice computed tomography (CT) of the thorax 
and abdomen were excluded. Prior to therapy, 
each patient was evaluated at the local multidisci-
plinary tumor (MDT) conference. Patients were 
scheduled for three PIPAC procedures (q4–6 
weeks) before re-evaluation at the MDT confer-
ence. To rule out extraperitoneal dissemination, a 
CT of the thorax and abdomen was performed at 
baseline and after every third PIPAC treatment. 
Based on a combination of tolerability, visual, 
radiological, cytological and histological regres-
sion, additional PIPAC treatment was planned.
Overall, 60 patients were screened according to the 
predefined inclusion and exclusion criteria, and 35 
patients were included (Figure 1). Primary end-
points were feasibility and response evaluation.
PIPAC
PIPAC has been previously described,14,16 but in 
brief, PIPAC is a laparoscopy-controlled adminis-
tration of pressurized intraperitoneal chemother-
apy, performed in a standard operating room 
equipped with a ventilation system that complies 
with the requirements of ISO norm 14644-1 class 
5. All procedures were performed by two certified 
PIPAC surgeons. Based on current evidence, 
patients with PM of colorectal or appendiceal ori-
gin were treated with oxaliplatin 92 mg/m2 in 150 
ml dextrose, while patients with PM of other origin 
were treated with a combination of cisplatin 7.5 
mg/m2 in 150 ml saline and doxorubicin 1.5 mg/
m2 in 50 ml saline. After prophylactic antibiotics (3 
g cefuroxime and 1.5 g metronidazole) and low-
molecular heparin, two balloon safety trocars (5 
and 12 mm; Applied Medical, Düsseldorf, 
Germany) were inserted through the abdominal 
wall guided by ultrasound, and a normothermic 
capnoperitoneum of 12 mmHg was obtained. 
After evacuation of ascites or peritoneal washing 
with 500 ml saline and mapping of the peritoneum 
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according to Sugarbaker’s peritoneal cancer index 
(PCI),9 multiple (if possible up to four) peritoneal 
biopsies from PM were obtained and the biopsy 
sites marked by metal clips (Figure 2). A 
CE-certified nebulizer (CapnoPen®, Capnomed, 
Villingendorf, Germany) connected to a standard 
intravenous high-pressure injector (MEDRAD® 
salient dual contrast injector, Bayer HealthCare, 
Leverkusen, Germany) was inserted. The chemo-
therapy administration was remote controlled, 
since all personnel left the operating room before 
administration of the chemotherapeutics. At a flow 
rate of 30 ml/min and a maximum pressure of 
200 pounds per square inch, chemotherapy was 
delivered within 5–10 min. After another 25 min of 
simple diffusion, the chemotherapy aerosol was 
evacuated with a closed line, through two sequen-
tial micro particle filters and the patient was closed 
with standard sutures. Postoperative pain was 
relieved by paracetamol (1 g × 4) and on-demand 
ibuprofen or morphine, if necessary. Postoperative 
nausea and vomiting (PONV) were minimized by 
perioperative dexamethasone and ondansetron (8 
mg × 2) at day 0–2. If the postoperative period 
was uneventful, the patients were informed and 
discharged at the day of PIPAC or the first postop-
erative day. PONV were recorded at the morning 
of the first postoperative day and postoperative 
pain was evaluated on a visual analog scale of 0–10. 
Blood samples were analysed at day 1 and 10 after 
Figure 1. Patient flow during PIPAC therapy.
CT, computed tomography; CRS, cyto-reductive surgery; ECOG PS, Eastern Cooperative Oncology Group performance 
status; EORTC-QLQC30, European Organisation for Research and Treatment of Cancer quality of life questionnaire; HIPEC, 
hyperthermic intraperitoneal chemotherapy.
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each PIPAC treatment to document toxicity. 
Screening for adverse events according to the 
Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 (National Cancer Institute) 
was performed according to 30 days definitions.
Feasibility
Feasibility was documented for both healthcare 
workers and patients. The environmental risk of 
chemotherapy exposure was documented through 
analysis of the air in the operating room (OR) and 
biologically, by taking blood samples of the two 
PIPAC surgeons, in order to detect platinum con-
centrations. The environmental measurements were 
performed by a national independent organization 
(Water and Environment, Life Science, Danish 
Technological Institute, Aarhus, Denmark).23
In terms of patient safety, PIPAC was feasible if 
(1) laparoscopic access was possible in 80% 
(28/35) of the patients, (2) if the PIPAC proce-
dure was completed in 80% of the patients, (3) if 
there were no CTCAE grade 4 or 5 events, and 
(4) if 80% of the patients were discharged within 
2 days after the procedure.
Response evaluation
Histology. If technically possible, four peritoneal 
quadrant biopsies were taken prior to each PIPAC 
procedure. The peritoneal biopsies were fixed in 
formalin (6–24 h) and embedded in paraffin. A 
total of three step sections were cut from the par-
affin-embedded tissue blocks and stained with 
haematoxylin-eosin (H&E), followed by a section 
immunostained for epithelial cell adhesion mole-
cule (Ep-CAM) and a final series of three step 
sections stained with H&E. If necessary, the 
pathologist used additional immunohistochemi-
cal stains, dependent on the particular biopsy and 
the type of primary tumor. For evaluation of the 
histological regression, the peritoneal regression 
grading score (PRGS) was used.28 The PRGS dis-
tinguishes between four grades of tumor regres-
sion, PRGS 1–4, depending on the ratio between 
regressive changes (inflammation, fibrosis, cell-
free mucin lakes, accumulation of macrophages, 
infarct-like necrosis) and the presence of vital 
cancer cells or classical necrosis. PRGS 1 (com-
plete response) is defined as no tumor cells pres-
ent; PRGS 2 (major response) is regressive 
changes predominant over tumor cells; PRGS 3 
(minor response) is predominance of tumor cells 
but regressive changes present, and PRGS 4 (no 
response) is no regressive changes present. The 
PRGS prior to the first PIPAC procedure is par-
ticularly important in order to document response 
to prior systemic chemotherapy, and since it 
forms a baseline for subsequent PIPAC response 
evaluation. As multiple biopsies are taken during 
each PIPAC procedure, it is recommended that 
the highest and the mean PRGS score should be 
reported in PIPAC publications.28
Cytology. A total of 150 ml of ascites or perito-
neal lavage fluid was retrieved and analysed, 
while the remaining intraperitoneal fluid was 
evacuated and discarded. The fluid was centri-
fuged, and smears of the sediment were analysed 
using conventional cytology (Papanicolaou and 
May–Giemsa Grünwald staining). Leftovers of 
the sediment were embedded in paraffin wax. 
One section from the paraffin block was stained 
with H&E. If necessary, further sections were cut 
for immunocytochemical analyses for markers 
such as calretinin, CDX2, carcinoembryonic 
antigen (CEA), cytokeratin (CK) 7, CK20, Ep-
CAM, Pax8 or maspin. For cytological evalua-
tion, a five-tiered score was used: malignant cells, 
suspicious cells, atypical cells, no malignant cells, 
other. In the data analysis, only malignant cells 
were defined as positive cytology.
Figure 2. (a) Punch biopsy of a PM. (b) The biopsy 
sites are marked by clips.
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Quality of life. Quality of life was monitored by 
the European Organisation for Research and 
Treatment of Cancer quality of life questionnaire 
(EORTC-QLQC30)29 at baseline, day 60, day 
120 and day 180.
Statistics
This was a descriptive study, and as such, a sub-
stantial number of patients were required to doc-
ument response evaluation and feasibility. The 
study group did not perform a power calculation 
a priori, but estimated that 35 patients should be 
included. Values are given as means or medians 
where appropriate. Comparisons were performed 
using a Wilcoxon Mann–Whitney test for contin-
uous data, p-values were two-tailed and a p-value 
of 0.05 was considered statistically significant. 
The statistical software Stata, version 13 (Stata 
Corp, Texas, USA) was used for statistical 
analysis.
Compliance with ethical standards
The study complies with the Helsinki Declaration 
and was approved by The Regional Committees 
on Health Research Ethics for Southern Denmark 
(Project-ID: S-20140211, www.clinicaltrials.gov 
NCT02320448), and all participants gave oral 
and written informed consent.
Results
During the study period, 35 patients with PM of 
any origin were treated with a total of 129 PIPAC 
procedures (median = 3, range 1–9). Primary 
tumor origin, previous systemic chemotherapy 
and demographic data are listed in Table 1. A 
total of 91% (32/35) of the patients had received 
palliative chemotherapy, and 3 patients had 
refused systemic chemotherapy. Overall, five 
patients (14%) received bidirectional chemother-
apy, with an interval of 2 weeks from systemic 
chemotherapy to PIPAC, and 1 week from 
PIPAC to systemic chemotherapy. Among the 35 
included patients, 30 and 27 patients were treated 
with two or three PIPAC procedures, respec-
tively, and 14 patients received four or more 
PIPACs (Figure 1). One patient was excluded 
due to nontreatment-related death after the first 
PIPAC procedure. The patient had a nonresect-
able cholangiocarcinoma with internal drainage 
of the bile duct. She suffered from stent occlusion 
and cholangitis starting 3 weeks after PIPAC 
treatment and died 3 months later.
Table 1. Demographic data and baseline 
characteristics.
Demographic variables  
 Age, years (range) 65 (41–84)
 Sex (male/female) 19/16
  Months from diagnosis 
of PM (range)
9.6 (1.5–130)
  ECOG performance 
status 0/1
32
  ECOG performance 
status 2
3
Previous treatment no. patients
 One-line palliative SC 22
 Two-line palliative SC 9
 >Two-line palliative SC 1
 Combination PIPAC/SC 5
Primary tumor origin no. patients
 Stomach 5
 Small bowel 2
 Cholangiocarcinoma 2
 Pancreas 3
 Appendix incl. PMP 4
 Colorectal 12
 MPM 1
 Ovarian 5
 MUP 1
 Primary tumor in situ 14
Baseline PM 
characteristics at PIPAC 1
 
PCI Score (SD)
  PCI when ⩾11 regions 
evaluated
15.37 (11.56)
  PCI when <11 regions 
evaluated
6.6 (4.10)
 PCI, total 14.11 (11.20)
Ascites volume no. patients
 0 ml 22
 (Continued)
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Demographic variables  
 1–500 ml 7
 501–1000 ml 3
 >1000 ml 3
ECOG, Eastern Cooperative Oncology Group; MPM, 
malignant peritoneal mesothelioma; MUP, metastasis of 
unknown primary; PCI, peritoneal cancer index; PIPAC, 
pressurized intraperitoneal aerosol chemotherapy; PM, 
peritoneal metastasis; PMP, pseudomyxoma peritoneii; 
SC, systemic chemotherapy; SD, standard deviation.
Table 1. (Continued)
Feasibility
No detectable concentration of platinum particles 
was found at analysis of the air in the OR during 
two consecutive PIPAC procedures. No traces of 
cisplatin were detected in the blood samples from 
the surgeons.
Laparoscopic access and completion of PIPAC 
was achieved in all patients, both at primary and 
subsequent procedures. The procedure time did 
not change from the first to the third PIPAC pro-
cedure (Table 2). Postoperative nausea, vomiting 
and pain scores remained low throughout the 
course of therapy. 80% (28/35) and 89% (24/27) 
of the patients were discharged within 24 h after 
the first and the third PIPAC, respectively.
Grading of adverse events during the course of 
therapy is presented in Figure 3. One life-threat-
ening adverse event was reported, as one of the 
patients had an iatrogenic perforation of the jeju-
num necessitating reoperation with primary 
suture on the first postoperative day. The perfora-
tion was just below the access site of the first tro-
car, and the bowel wall was otherwise intact, 
which makes a mechanical perforation most plau-
sible. A total of four patients had severe adverse 
events: One patient had diarrhea necessitating 
hospitalization, another had a small bowel 
obstruction, a third had duodenal obstruction 
and the fourth patient had cholestasis. Most 
patients with moderate adverse events had uri-
nary retention in the early postoperative period.
Response evaluation
Based on the PRGS scores prior to PIPAC 1 and 
PIPAC 3, 67% of the patients had an objective 
tumor response and the overall mean PRGS score 
was reduced from 2.05 to 1.54 (p = 0.0006). 
Cytologically, data from both PIPAC 1 and PIPAC 
3 were available, and free intraperitoneal tumor cells 
were eradicated in 5/22 (23%) patients (Table 2).
The quality of life according to the EORTC-
QLQC30 global health score (Figure 4), and 
based on symptom and function scores, was sta-
ble between baseline and day 60, while there were 
not enough data from day 120 and day 180 for 
statistical analysis.
Discussion
The PIPAC procedure was feasible and well tol-
erated for both healthcare workers and patients 
with no occupational exposure to chemother-
apy.23 Laparoscopic access to the abdominal cav-
ity and completion of PIPAC was achieved in all 
patients. PIPAC was repeatable in 30/35 patients 
with low toxicity and procedure related complica-
tions, but one life-threatening event occurred, 
due to unrecognized bowel lesion during open 
access to the abdomen, which is seen in 0.1–0.2% 
of all laparoscopies,30 and this was not related to 
the chemotherapy. This is the first prospective 
study assessing both cytological and histological 
response based on PRGS in a large series of 35 
consecutive patients treated with PIPAC. PIPAC 
induced a significant histological response in 
patients with PM of different origin, and an objec-
tive tumor response with reduction of the mean 
PRGS score was observed in 67% of the patients. 
PIPAC eradicated free intraperitoneal tumor cells 
in 23% of the patients. Furthermore, PIPAC sta-
bilized the patients’ quality of life, as documented 
by the EORTC-QLQC30 global health score, 
which has also been previously described.21,31
This study is important, since the results were 
obtained by adhering to a strict predefined strategy 
to evaluate the response to PIPAC. Biopsies and 
peritoneal lavage cytology were mandatory at base-
line and during each PIPAC treatment, and the 
effect of both previous treatment strategies (i.e. sys-
temic chemotherapy) and PIPAC could be moni-
tored. The actual effect of systemic chemotherapy 
has been difficult to evaluate in previous PIPAC 
studies.17 In general, the effect of PIPAC has been 
defined and monitored by different methods 
(RECIST, PCI score, quality of life, histopatho-
logical tumor regression, median survival and 
changes in gene expression17), but none of these are 
without limitations. The proposed response evalua-
tion strategy in the present study was based on 
M Graversen, S Detlefsen et al.
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Table 2. Feasibility and response evaluation data.
Procedures  
Total no. PIPAC procedures 129  
 PIPACs/pt, mean (SD) 3.66 (1.95)  
 PIPACs/pt, median (range) 3 (1–9)  
Technical aspects PIPAC 1 (n = 35) PIPAC 3 (n = 27)  
Intraperitoneal access, no. patients (%) 35 (100%) 27 (100%)  
Procedure time, minutes (range) 100 (71–156) 92 (77–125)  
Days of admission, median (range) 1 (1–4) 1 (0–3)  
Discharge day 0/1, no. patients (%) 28 (80%) 24 (89%)  
Pain/PONV  
Postoperative pain*, median (range) 3 (0–10) 3 (0–7)  
Postoperative nausea, no. patients  
 None 24 14  
 Mild 2 4  
 Moderate 1 3  
 Severe 8 5  
Postoperative vomiting, no. patients  
 None 26 18  
 1 vomit 2 1  
 2–3 vomits 3 2  
 >3 vomits 4 5  
Response evaluation PIPAC 1 PIPAC 3  
PRGS, mean (SD) 2.05 (0.66) 1.54 (0.52) p = 0.0006
PRGS, maximum value 4 3  
PRGS improvement, patients (%) 18/27 (67%)  
Malignant cells in peritoneal lavage 13/22 (59%) 9/22 (41%)  
  Conversion nonmalignant → 
malignant
1/22 (4.5%)  
  Conversion malignant → 
nonmalignant
5/22 (23%)  
 No conversion 8/22 (36%)  
* Visual Analog Scale 1–10.
PIPAC, pressurized intraperitoneal aerosol chemotherapy; PONV, postoperative nausea and vomiting; PRGS, peritoneal 
regression grading score; Pt, patient; SD, standard deviation.
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repeated histological biopsies for PRGS assessment 
and peritoneal lavage cytology. All biopsy sites were 
marked by clips to reduce the risk of sampling error 
when taking the subsequent biopsies (Figure 2), 
but this method may also harbour some limitations. 
In a few cases, the clips were displaced, or the 
access to clip-marked elements were restricted by 
adhesions. Next, the distribution of the aerosolized 
chemotherapeutics might have been inhomogene-
ous, which in theory could have led to different his-
tological regression scores, depending on the 
distance between the biopsy sites and the nebu-
lizer.32 This supports future studies with both histo-
logical and cytological evaluation.
Eligibility for cytoreductive surgery is usually 
based on the PCI score,9 which PIPAC has been 
shown to improve.33 We find the PCI valuable 
to describe the study population at the index 
PIPAC procedure, but based on the adhesions 
caused by earlier resections, the two-trocar 
strategy and the treatment-induced peritoneal 
changes, PCI is a suboptimal tool for evaluation 
of response to PIPAC as the PCI cannot differ 
between macroscopic progression and treat-
ment-induced fibrosis. Still, resectability assess-
ment is important, since a fraction of patients 
may become candidates for cytoreductive sur-
gery,34 and despite the mentioned visual limita-
tions, the Dutch Seven Regions Count could 
serve as a simple macroscopic surveillance tool 
during the course of PIPAC therapy.35 CT of 
the thorax and abdomen is used to detect extra-
peritoneal lesions but has a low sensitivity for 
low-volume PM. However, future studies 
should investigate, whether diffusion-weighted 
gadolinium enhanced magnetic resonance imag-
ing (MRI) is a useful additional response evalu-
ation modality.36–38
While this study documents PIPAC treatment 
feasibility and efficacy in a broad range of referred 
patients with PM, its interpretation is limited due 
to the heterogeneous study population with 10 
different primary tumors and 14 patients with a 
primary tumor in situ. Overall five patients were 
treated with a combination of systemic chemo-
therapy and PIPAC, which impedes isolated 
interpretation of the PIPAC treatment. The bidi-
rectional concept of alternating PIPAC and sys-
temic chemotherapy may improve overall 
outcome and based on the available data bidirec-
tional therapy does not seem to carry an increased 
risk of complications.33,39
Figure 3. Adverse events.
CTCAE, Common Terminology Criteria for Adverse Events.
Figure 4. Global quality of life at baseline (day 0) and 
after 60 days according to EORTC-QLQC30.
EORTC-QLQC30, European Organisation for Research and 
Treatment of Cancer quality of life questionnaire.
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Preliminary survival data from PIPAC studies are 
interesting with reported survival rates in PM 
patients of 11–16 months,20,21,24–27,40 but study 
size, design and patient heterogeneity are major 
problems. The present study was not powered for 
subgroup analyses regarding survival. We chose 
to focus on an objective response evaluation based 
on data from the first and third PIPAC, as PIPAC 
treatment was planned in series of three. A total 
of 14 patients received more than three PIPACs, 
but due to the low patient number and different 
tumor types, the effect of more than three PIPAC 
procedures still has to be investigated.
Conclusion
Intraperitoneal chemotherapy administered 
through the PIPAC drug-delivery system was fea-
sible and may be safely implemented at a tertiary 
referral center. Using a strict and uniform response 
evaluation process, PIPAC can induce statistically 
significant histological regression in a population 
of patients with PM, and an objective tumor 
response in two out of three patients. Cytologically, 
free intraperitoneal tumor cells are eradicated in 
selected patients, but the clinical impact of this 
finding in patients with visible PM is still unclear. 
More research in strategies and tools for objective 
response evaluation is needed, and the present 
data should be confirmed in larger PIPAC studies 
focusing on specific diseases before embarking on 
randomized multicenter trials.
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